Inflammatory response to percutaneous coronary intervention in stable coronary artery disease

Peter S Munk1, Unni M Breland, Pål Aukrust

  • 1Department of Cardiology, Stavanger University Hospital, Postbox 8100, 4068 Stavanger, Norway. munk@lyse.net

Insights

Percutaneous coronary intervention (PCI) triggers complex inflammatory responses in stable coronary artery disease (CAD). While some inflammatory markers increase early, others decrease, with minor influences from stent type or access site.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Interventional Cardiology

Background:

  • Percutaneous coronary intervention (PCI) is a common procedure for stable coronary artery disease (CAD).
  • PCI can induce plaque rupture, potentially triggering inflammatory responses.
  • Understanding these inflammatory responses is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To evaluate the acute inflammatory response to PCI in patients with stable CAD.
  • To analyze plasma levels of various inflammatory mediators following PCI.
  • To investigate the influence of stent type, access site, and medication on these responses.

Main Methods:

  • Serial plasma measurements of inflammatory mediators in 36 stable CAD patients post-PCI.
  • Comparison of bare metal stent (BMS) versus drug-eluting stent (DES) groups.
  • Analysis of inflammatory marker changes over 7 days, considering access site and glycoprotein-IIb/IIIa-inhibitor use.

Main Results:

  • Significant early increases observed in C-reactive protein (CRP), Pentraxin 3, Vascular Cell Adhesion Molecule-1 (VCAM-1), CD40 ligand, monocyte chemoattractant protein, CCL21, and CXCL16.
  • E-selectin, P-selectin, Interleukin-8, CCL19, and RANTES showed significant decreases or variable patterns.
  • Drug-eluting stents (DES) were associated with lower VCAM-1 and RANTES levels compared to BMS.
  • Femoral access site correlated with higher CRP; glycoprotein-IIb/IIIa-inhibitors with higher CD40L and RANTES.

Conclusions:

  • PCI elicits a complex and dynamic inflammatory response in stable CAD patients.
  • Simultaneous measurement of multiple inflammatory markers is necessary for comprehensive characterization.
  • Stent type, access site, and specific medications have a minor impact on the overall inflammatory profile post-PCI.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Acute Inflammation I: Inflammatory Response01:26

Acute Inflammation I: Inflammatory Response

Acute inflammation is a rapid, short-lived physiological response to tissue injury or infection, designed to eliminate harmful agents and initiate repair. This tightly regulated process typically lasts from minutes to several days and is triggered by factors such as microbial invasion, physical trauma, or chemical injury.Recognition and Mediator ReleaseThe inflammatory response begins when resident immune cells—such as mast cells, macrophages, and dendritic cells—detect damage-associated...